Impact of Prior Cancer History on the Clinical Outcomes in Advanced Breast Cancer: A Propensity Score–Adjusted, Population-Based Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Despite the rapid growing of cancer survivors, prior cancer history is a commonly adopted exclusion criterion. Whether prior cancer will impact the survival of patients with advanced breast cancer (ABC) remains uncertain. Materials and Methods Patients with ABC diagnosed between 2004 and 2010 were identified using Surveillance, Epidemiology, and End Results (SEER) database. Timing, stage, and type were used to characterize prior cancer. Multivariable analyses using propensity score–adjusted Cox regression and competing risk regression were conducted to evaluate the prognostic effect of prior cancer on overall survival (OS) and breast cancer-specific survival (BCSS). Results A total of 14,176 ABC patients were identified, of whom 10.5% carried a prior cancer history. The most common type of prior cancer was female genital cancer (32.4%); more than half (51.7%) were diagnosed at localized stage; most were diagnosed more than 5 years (42.9%) or less than 1 year (28.3%) prior to the index cancer. In multivariate analyses, patients with prior cancer presented a slightly worse OS (hazard ratio, 1.18; 95% confidence interval [CI], 1.07 to 1.30; p=0.001) but a better BCSS (subdistribution hazard ratio, 0.64; 95% CI, 0.56 to 0.74; p < 0.001). In subset analyses, no survival detriment was observed in patients with prior malignancy from head and neck or endocrine system, at in situ or localized stage, or diagnosed more than 4 years. Conclusion Prior cancer provides an inferior OS but a superior BCSS for patients with ABC. It does not affect the survival adversely in some subgroups and these patients should not be excluded from clinical trials.
Abstract
Purpose Despite the rapid growing of cancer survivors, prior cancer history is a commonly adopted exclusion criterion. Whether prior cancer will impact the survival of patients with advanced breast cancer (ABC) remains uncertain. Materials and Methods Patients with ABC diagnosed between 2004 and 2010 were identified using Surveillance, Epidemiology, and End Results (SEER) database. Timing, stage, and type were used to characterize prior cancer. Multivariable analyses using propensity score–adjusted Cox regression and competing risk regression were conducted to evaluate the prognostic effect of prior cancer on overall survival (OS) and breast cancer-specific survival (BCSS). Results A total of 14,176 ABC patients were identified, of whom 10.5% carried a prior cancer history. The most common type of prior cancer was female genital cancer (32.4%); more than half (51.7%) were diagnosed at localized stage; most were diagnosed more than 5 years (42.9%) or less than 1 year (28.3%) prior to the index cancer. In multivariate analyses, patients with prior cancer presented a slightly worse OS (hazard ratio, 1.18; 95% confidence interval [CI], 1.07 to 1.30; p=0.001) but a better BCSS (subdistribution hazard ratio, 0.64; 95% CI, 0.56 to 0.74; p < 0.001). In subset analyses, no survival detriment was observed in patients with prior malignancy from head and neck or endocrine system, at in situ or localized stage, or diagnosed more than 4 years. Conclusion Prior cancer provides an inferior OS but a superior BCSS for patients with ABC. It does not affect the survival adversely in some subgroups and these patients should not be excluded from clinical trials.
참고문헌 (30)
- Siegel RL, "Cancer statistics, 2018", CA Cancer J Clin, 68, pp.7~30 (2018)
- Jemal A, "Annual report to the nation on the status of cancer, 1975-2014, featuring survival", J Natl Cancer Inst, 109, pp.djx030~ (2017)
- Hayat MJ, "Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results(SEER)Program", Oncologist, 12, pp.20~37 (2007)
- Murphy CC, "Prevalence of prior cancer among persons newly diagnosed with cancer : an initial report from the Surveillance, Epidemiology, and End Results program", JAMA Oncol, 4, pp.832~836 (2018)
- Zhou H, "Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer : a pan-cancer analysis of the SEER database", Int J Cancer, 143, pp.1569~1577 (2018)
- "Clinical Practice Guidelines in Oncology: Breast Cancer. version 3.2018" (2018)[URL]
- Lemieux J, "Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials", J Clin Oncol, 26, pp.4458~4465 (2008)
- Kim ES, "Broadening eligibility criteria to make clinical trials more representative : American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement", J Clin Oncol, 35, pp.3737~3744 (2017)
- Gerber DE, "Impact of prior cancer on eligibility for lung cancer clinical trials", J Natl Cancer Inst, 106, pp.dju302~ (2014)
- "Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies" (2019)[URL]
- Laccetti AL, "Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual", J Natl Cancer Inst, 107, pp.djv002~ (2015)
- Laccetti AL, "Prior cancer does not adversely affect survival in locally advanced lung cancer : a national SEER-medicare analysis", Lung Cancer, 98, pp.106~113 (2016)
- Gerber DE, "Should criteria for inclusion in cancer clinical trials be expanded?", J Comp Eff Res, 4, pp.289~291 (2015)
- Shameem R, "Secondary primary cancers in male breast cancer survivors", J Clin Oncol, 32(26 Suppl), pp.129~ (2014)
- Gray RJ, "A class of K-sample tests for comparing the cumulative incidence of a competing risk", Ann Stat, 16, pp.1141~1154 (1988)
- Fine JP, "A proportional hazards model for the subdistribution of a competing risk", J Am Stat Assoc, 94, pp.496~509 (1999)
- Scrucca L, "Regression modeling of competing risk using R : an in depth guide for clinicians", Bone Marrow Transplant, 45, pp.1388~1395 (2010)
- Schoenfeld D, "Partial residuals for the proportional hazards regression model", Biometrika, 69, pp.239~241 (1982)
- Austin PC, "An introduction to propensity score methods for reducing the effects of confounding in observational studies", Multivariate Behav Res, 46, pp.399~424 (2011)
- Yang D, "A unified approach to measuring the effect size between two groups using SAS", SAS Global Forum, 1~6 (2012)
- Davidson NE, "Incident cancer in cancer survivors : when cancer lurks in the background", JAMA Oncol, 4, pp.836~837 (2018)
- Bluethmann SM, "Anticipating the"Silver Tsunami" : prevalence trajectories and comorbidity burden among older cancer survivors in the United States", Cancer Epidemiol Biomarkers Prev, 25, pp.1029~1036 (2016)
- Ledford H, "Cancer researchers push to relax rules for clinical trials", Nature, 556, pp.12~13 (2018)
- Dinh KT, "Risk of prostate cancer mortality in men with a history of prior cancer", BJU Int, 117, pp.E20~8 (2016)
- Smyth EC, "Exclusion of gastrointestinal cancer patients with prior cancer from clinical trials: is this justified?", Clin Colorectal Cancer, 15, pp.e53~e59 (2016)
- Schonberg MA, "Causes of death and relative survival of older women after a breast cancer diagnosis", J Clin Oncol, 29, pp.1570~1577 (2011)
- Baldwin LA, "Ten-year relative survival for epithelial ovarian cancer", Obstet Gynecol, 120, pp.612~618 (2012)
- Lee JH, "Recurrence of gastric cancer in patients who are disease-free for more than 5 years after primary resection", Surgery, 159, pp.1090~1098 (2016)
- Shintani T, "A retrospective long-term follow-up study of stereotactic body radiation therapy for non-small cell lung cancer from a single institution : incidence of late local recurrence", Int J Radiat Oncol Biol Phys, 100, pp.1228~1236 (2018)
- Ahn DH, "Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer", Clin Lung Cancer, 14, pp.644~650 (2013)